Research programme: p38 MAP kinase inhibitors - LEO Pharma
Alternative Names: p38 MAP kinase inhibitors research programme - LEO PharmaLatest Information Update: 08 Apr 2008
At a glance
- Originator LEO Pharma
- Class Benzophenones; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 08 Apr 2008 Discontinued - Preclinical for Inflammation in Denmark (unspecified route)
- 07 Sep 2004 Data presented at the 18th International Symposium on Medicinal Chemistry (ISMC-2004) have been added to the pharmacokinetics and Inflammation pharmacodynamics section
- 28 Jan 2004 Preclinical trials in Inflammation in Denmark (unspecified route)